Lutetium-177 (Lu-177) Market: Advancing Nuclear Medicine
Stats ID: 5327
| Delivery Format: Databook
| Last Updated: October 2024
| Delivery:Immediate
Lutetium-177 (Lu-177) Market Key Highlights:
Market Size (2023): USD 1,578 Million
Projected Market Size (2034): USD 8,875 Million
CAGR (2023-2034): 17%
Pricing Analysis:
Price Growth
Regional Variations
Volume Analysis:
2023 to 2034 Volume
Import-Export Data
Major Importers
Major Exporters
Market Historic Sales
Total sales volume, year-over-year growth, product categories, and market share.
Revenue Estimation
Forecasting future revenues based on historical data, market trends, and economic indicators.
Sales by Region
Breakdown of sales performance across different geographical areas.
Revenue by Manufacturer
Analysis of revenue contributions from different manufacturers in the market.
Price by Manufacturer
Examination of pricing strategies adopted by various manufacturers.
Lutetium-177 (Lu-177) Market Definition
The Lutetium-177 (Lu-177) market is a prominent sector of the advanced materials industry. This industry deals in the extraction and distribution of lutetium compounds across the world. These elements are silvery-white in color and have a density of 9.84 g/cm3. The atomic mass of this compound is 174.967 amu, and a melting point of 1,663 °C. The growing developments in radiopharmaceutical therapy, coupled with increased applications in diagnostic imaging technology, have shaped the industry in a positive way. This market is expected to rise significantly with the growth in the pharmaceutical industry across the world.
The growing use of lutetium-177 (Lu-177) in the healthcare sector for several applications, such as cancer treatment, radiopharmaceutical therapy, and diagnostic imaging, has boosted the market growth. Also, the increased application of High Specific Activity Lutetium-177 in tumor treatment coupled with developments in radioligand therapies across the world is likely to contribute positively to the industry. Moreover, the rising application of these compounds in scientific research, along with the increased usage of lutetium-177 (Lu-177) in the nuclear industry, is expected to drive the growth of the lutetium-177 (Lu-177) market.
Advancements in targeted radionuclide therapy along with developments in Carrier-Added Lutetium-177 is expected to create ample growth opportunities for the market players in the future. In April 2024, Novartis announced that the Food and Drug Administration approved Lutathera. Lutathera (lutetium-177 (Lu-177)) is a radioactive drug that is effective for treating pediatric patients suffering from gastroenteropancreatic neuroendocrine tumors (GEP-NETs).
